Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Intensive Case Management for Substance Use Disorders (RCT) (ICM)

13. november 2026 oppdatert av: Psychiatric Services Aargau AG

Intensive Case Management for Patients With Substance Use Disorders and Complex Psychosocial Needs: A Randomized Controlled Trial

This study aims to assess the effectiveness of Intensive Case Management (ICM) compared to TAU. Economically, this study could contribute to more cost-effective treatments, since relatively expensive inpatient care could be relieved of patients not benefiting from inpatient care, and those patients would receive a more adequate and effective treatment. Our first goal is to evaluate the effectivenessof ICM as a treatment for people with SUDs in the canton of Aargau compared to TAU. To assess the effectiveness, the outcome measured will be the RICID and the NOIA. Furthermore, the increase in Quality of Life and Social Integration with appropriate Questionnaires of Patients in ICM is compared to Patients in TAU. The second goal of this study is to evaluate the cost-effectiveness of ICM for the aforementioned patients compared to TAU.

Case Management, especially for people with multiple and complex needs, is an intervention designed to enhance coordination and continuity of support and care (Vanderplasschen et al. 2019). Also, for people with high levels of disability due to mental illness, ICM is widely claimed to be an evidence-based and cost-effective program (King, 2006). Furthermore, key ICM components, linkage and retention, seem to show the largest effect sizes (SMD = 0.33, 95% CI 0.18-0.48) in ICM. Linkage and retention are necessary prerequisites that keep patients with SUDs in contact with health services (Vanderplasschen et al., 2019). Although evidence across all outcome measures, according to the same author, is significant and positive, but small (SMD = 0.18, 95% CI [0.07-0.28]). There is mixed evidence in outcomes such as health outcomes (SMD = -0.16, 95%CI [-0.40, 0.08]), social functioning (SMD = 0.14, 95% CI [-0.01, 0.28]) or reduced substance use (SMD = 0.10, 95% CI [-0.02, 0.21]).

Moreover, ICM and closely related models (i.e., Assertive Community Treatment, ACT) show a Reduction in Cumulative Inpatient Days (RICID) and a reduction in inpatient admissions (Dietrich et al., 2017; Burns et al., 2007). This is a common outcome in ICM literature and is also a measure for reductions in healthcare costs, since inpatient treatments are bound to high costs.

In this study, there are mainly four groups of patients with SUDs that, despite previous or present linkages to health services, do need further or a different kind of treatment. Those patients are:

  • People with low treatment satisfaction and high usage of health and social services: These patients, despite their previous treatments and social connections, do not improve sufficiently and continue to utilize healthcare services.
  • people that already are in complex helping systems and make use of a high number of treatments but show a high need for coordination to be effective
  • patients with dual diagnosis, with SUD being one of those in combination with, e.g., schizophrenia, personality disorders and anxiety disorders and would need intense and continuous care.
  • people that, due to their clinical picture or other difficulties in life, do not have access to existing treatments (anymore) and fall through the social network. It includes people without permanent addresses, people with precarious housing conditions or socially isolated people, independent of their employment status.

Sex and gender will be treated as potential covariates and will be considered in the analysis.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Studietype

Intervensjonell

Registrering (Antatt)

180

Fase

  • Ikke aktuelt

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Canton of Aargau
      • Windisch, Canton of Aargau, Sveits, 5210
        • Rekruttering
        • PDAG
        • Ta kontakt med:
        • Hovedetterforsker:
          • Johannes Senesi, Msc

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år til 64 år (Voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • 4 or more inpatient admissions in the last 24 months
  • Diangosed SUD
  • Residence or temporary stay in the canton of Aargau

Exclusion Criteria:

  • any emergency situation requiring psychiatric or hospital admissions
  • inability to give informed consent
  • acute, unstable psychotic symptoms
  • acute risk of harm to self or others
  • insufficient german language skills

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Helsetjenesteforskning
  • Tildeling: Randomisert
  • Intervensjonsmodell: Crossover-oppdrag
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Experimental

receives ICM immediately

Intensive Case Management for People with SUDs and complex psychosocial needs is an outreach-based intervention aimed at linking participants to health services and coordinating them. Additionally, two focus points are implemented to increase adherence and engagement:

  1. Intensive crisis intervention: Offering immediate, flexible support in acute crises, preventing escalations early and strengthening the stability of patients.
  2. Relationship continuity: Establishing an empathetic & constant presence, breaking down barriers, creating a trustful, stable relationship.
Aktiv komparator: Waiting List

Same as Experimental, only with 6-Month TAU-Waiting List before ICM

TAU will take place for 6 months before starting with ICM

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Number of Inpatient Admissions (Health Service utilisation)
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Admissions into psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Number of Inpatient Days (Health Service utilisation)
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Number of Inpatient Days in psychiatric care. This measure only reflects the presence of patients on the ward and is strenghtend by Continuity of Care, Linking and Retention.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
WHOQoL-BREF
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Quality of Life

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
SFQ
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Social Functioning Questionnaire

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
ASSIST
Tidsramme: 6 Months (exploratory), 24 months (exploratory)

Substance use characteristics

6 Months (exploratory), 24 months (exploratory)
Continuity of Care (Brice-Boxerman)
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Continuity of Care describes timeframes of the health services used outside the ward.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Linking
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Linking describes the successful referral to health services not captured by the primary endpoint (meaning, outside the ward) and is the central mechanism of this Intensive Case Management.

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
Retention
Tidsramme: 6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)

Retention describes the voluntary staying of patients in the ICM treatment

6 Months (confirmatory in RCT phase), 24 months (exploratory post-waiting list)
BSCL
Tidsramme: 6 Months (exploratory), 24 months (exploratory)

Brief Symptoms Checklist, measuring the most common somatic and psychological symptoms found in psychiatric care

6 Months (exploratory), 24 months (exploratory)
EQ-5D-5L
Tidsramme: 6 Months (exploratory), 24 months (exploratory)

EuroQOL Quality of Life questionnaire for assessing cost-effectiveness (Incremental cost-effectiveness ratio, ICER)

6 Months (exploratory), 24 months (exploratory)

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

4. juli 2026

Primær fullføring (Antatt)

1. juli 2029

Studiet fullført (Antatt)

1. juli 2029

Datoer for studieregistrering

Først innsendt

13. november 2026

Først innsendt som oppfylte QC-kriteriene

13. november 2026

Først lagt ut (Faktiske)

19. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

19. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

13. november 2026

Sist bekreftet

1. november 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • PDAG-ICM
  • HumRes68440 (Annen identifikator: Human Research Switzerland (HumRes))

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .